Tokyo, Japan

Masakazu Homma

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Masakazu Homma: Innovator in Antibody Technology

Introduction

Masakazu Homma is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of four patents to his name, his work has advanced the understanding and application of antibody technology.

Latest Patents

Homma's latest patents focus on antibodies with non-natural amino acids introduced therein. These inventions relate to monoclonal antibodies or antibody fragments that include at least one lysine derivative in the constant region of the human IgG antibody. His patents also cover modified antibodies, nucleic acids encoding these antibodies, vectors containing the nucleic acids, and methods for producing the antibodies or fragments. These innovations have the potential to enhance therapeutic applications in medicine.

Career Highlights

Throughout his career, Masakazu Homma has worked with notable companies such as Kyowa Kirin Co., Ltd. and Riken Corporation. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Kensaku Sakamoto and Kazumasa Ohtake. Their collaborative efforts have further enriched the research environment and fostered innovation in antibody technology.

Conclusion

Masakazu Homma's contributions to the field of biotechnology, particularly in antibody development, highlight his role as a key innovator. His patents and collaborations reflect a commitment to advancing medical science through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…